Adrenergic and Endothelin B Receptor–Dependent Hypertension in Dopamine Receptor Type-2 Knockout Mice

Xiao Xi Li, Martin Bek, Laureano D. Asico, Zhiwei Yang, David K. Grandy, David S. Goldstein, Marcelo Rubinstein, Gilbert M. Eisner, Pedro A. Jose

Abstract—Polymorphism of the dopamine receptor type-2 (D$_2$) gene is associated with essential hypertension. To assess whether D$_2$ receptors participate in regulation of blood pressure (BP), we studied mice in which the D$_2$ receptor was disrupted. In anesthetized mice, systolic and diastolic BPs (in millimeters of mercury) were higher in D$_2$ homozygous and heterozygous mutant mice than in D$_2$+/+ littermates. BP after α-adrenergic blockade decreased to a greater extent in D$_2$−/− mice than in D$_2$+/+ mice. Epinephrine excretion was greater in D$_2$−/− mice than in D$_2$+/+ mice, and acute adrenalectomy decreased BP to a similar level in D$_2$−/− and D$_2$+/+ mice. An endothelin B (ET[B]) receptor blocker for both ET(B1) and ET(B2) receptors decreased, whereas a selective ET(B1) blocker increased, BP in D$_2$−/− mice but not D$_2$+/+ mice. ET(B) receptor expression was greater in D$_2$−/− mice than in D$_2$+/+ mice. In contrast, blockade of ET(A) and V$_1$ vaspressin receptors had no effect on BP in either D$_2$−/− or D$_2$+/+ mice. The hypotensive effect of an AT$_1$ antagonist was also similar in D$_2$−/− and D$_2$+/+ mice. Basal Na$^+$.K$^+$-ATPase activities in renal cortex and medulla were higher in D$_2$+/+ mice than in D$_2$−/− mice. Urine flow and sodium excretion were higher in D$_2$+/+ mice than in D$_2$−/− mice before and after acute saline loading. Thus, complete loss of the D$_2$ receptor results in hypertension that is not due to impairment of sodium excretion. Instead, enhanced vasoreactivity in the D$_2$ mutant mice may be caused by increased sympathetic and ET(B) receptor activities. (Hypertension. 2001;38:303-308.)

Key Words: dopamine receptors, dopamine receptors, endothelin Na$^+$.K$^+$ transporting ATPase kidney

Dopamine can regulate cardiovascular function by its actions on central cardiovascular centers, the pituitary and adrenal glands, kidney, cardiac and vascular smooth muscle, and the sympathetic nervous system.1,2 Effects of dopamine are mediated by dopamine receptor type-1 and type-2 (D$_1$- and D$_2$-)-like receptors that belong to the G protein–coupled receptor family.1,2 Both D$_1$- and D$_2$-like receptors have been shown to regulate arterial blood pressure (BP).1,2 Genetic hypertension in rodents and humans has been shown to be associated with decreased activity of D$_1$-like receptors in the kidney and central nervous system.1,2 Decreased D$_2$-like dopaminergic activity in the central nervous system has been reported in essential hypertension.1,4 Several studies in animal models of genetic hypertension also support the notion of altered central D$_2$-like dopaminergic activity in hypertension.5,6 However, 3 D$_2$-like dopamine receptors, D$_2$, D$_3$, and D$_4$, exist, and which of the 3 cloned D$_2$-like receptors participate in the D$_2$-like regulation of BP is unclear.1,3 Disruption of D$_3$ receptors in mice produces hypertension mediated, at least in part, by activation of the renin-angiotensin system.7 The D$_2$ receptor could be involved in D$_2$-like-mediated hypertension because it is the major D$_2$-like dopamine receptor.3,8–11 Moreover, BP decreased when a segment of chromosome 8 that contained the D$_2$ receptor gene was transferred from a normotensive Brown Norway rat to a spontaneously hypertensive rat background.12

Several variants of the human D$_2$ dopamine receptor have been reported.13 Abnormalities of D$_2$ receptor genes could play a role in the pathogenesis of essential hypertension, because the association of a D$_2$ dopamine receptor polymorphism with obesity and hypertension has been reported.14 To determine whether D$_2$ receptors play a role in the regulation of BP, we measured arterial pressure in congenic B6 mice mutants for the D$_2$ receptor.8,9 Because D$_2$-like receptors have been shown to interact with vasopressor systems,1,6,15,16 interactions between D$_2$ receptors and other vasopressor systems were also studied.

Methods

D$_2$ Receptor–Deficient Mice

The original F$_2$ hybrid strain (129/SvXC57BL/6J, Oregon Health Sciences University, Portland) that contained the mutated D$_2$ recep-

Received October 23, 2000; first decision December 7, 2000; revision accepted March 1, 2001.
From the Departments of Pediatrics (X.X.L., M.B., L.D.A., Z.Y., P.A.J.), Physiology and Biophysics (Z.Y., P.A.J.), and Medicine (G.M.E.), Georgetown University Medical Center, Washington, DC; the Departments of Physiology and Pharmacology (D.K.G.), Oregon Health Sciences University, The Vollum Institute, Portland, Ore; the National Institute of Neurological Disorders and Stroke (D.S.G.), Bethesda, Md; and Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (M.R.), Universidad de Buenos Aires, Argentina.
Correspondence to Pedro A. Jose, MD, PhD, Professor of Pediatrics and Physiology and Biophysics, Georgetown University Medical Center, 3800 Reservoir Rd NW, Washington, DC 20007. E-mail josep@gunet.georgetown.edu

Hypertension is available at http://www.hypertensionaha.org
tor allele was backcrossed to wild-type C57BL/6J for 5 generations and genotyped. These mice acquired normal motor skills without tremor, ataxia, or abnormal stance or posture but had decreased initiation of movement. All studies were approved by the Georgetown University Animal Care and Use Committee.

**BP and Renal Function Studies**

Mice were anesthetized with pentobarbital 50 mg/kg IP, placed on a heated board to maintain body temperature at 37°C, and tracheotomized. Mice were euthanized (pentobarbital 100 mg/kg) at the conclusion of the study.

**Effect of Agonists and Antagonists on BP**

Because preliminary studies indicated that arterial pressures were higher in D2−/− than D2+/+ mice, we determined the mechanism of increase in BP by intravenous infusion of antagonists of pressor agents. After a 60-minute stabilization period, drugs were infused in random order: 1-[(β-mercaptopo-β,β-cyclopentamethylepenepropionic acid)-2-(O-methyl)-tyrosine] arginine vasopressin (V1 vasopressin antagonist; Peninsula Laboratories, Inc) 10 μg/kg IV over 30 seconds; BQ-610 (endothelin receptor antagonist, ET[1]; Peninsula) 100 μg·kg−1·min−1 for 10 minutes; BQ-788 (endothelin B ET[1]/ET[2] antagonist; Peninsula) 6.6 μg·kg−1·min−1 for 15 minutes; RES-701-1 (ET[1] antagonist; American Peptide) 100 μg·kg−1·min−1 for 1 hour; phenolamine (α-adrenergic antagonist; Research Biochemicals International) 5 mg·kg−1·min−1 for 30 minutes; and losartan (AT1 antagonist) 3 mg/kg IV over 30 seconds. BP was allowed to stabilize at preinfusion values for 30 to 60 minutes before new drug administration. These antagonists block the vasopressor effects of their respective agonists: 40 μL of various concentrations of vasopressin, phenylephrine, endothelin-1 (ET-1), and angiotensin II, respectively, given over 30 seconds. Effects on BP of bolus injections of ET[1] agonist sarafotoxin S6c 0.01 to 1.0 nmol/kg (American Peptide) and ET-1 0.1 to 1.3 pmol/kg were also studied.

**Adrenalectomy**

Effect of adrenalectomy on BP was also studied in some mice. After a midline abdominal incision, adrenal gland was separated from kidney, ligated, crushed with forceps, and excised. BP readings were obtained after a 20-minute stabilization period.

**Immunoblotting Studies**

Because blockade of ET(B) receptors normalized BP in D2−/− mice (see Results), we immunoblotted for ET(B) receptors (Maine Bio-technology Services, Inc) of liver; ET-1 has been reported to induce constriction of hepatic circulation through both ET(A) and ET(B) receptors. Renal D2 receptors were also immunoblotted with purified rat striatum as positive control (Chemicon). Negative controls included rabbit IgG instead of primary antibody, secondary antibody alone, and D2 antibody preadsorbed with immunizing peptide. D2-specific bands (49 and 98 kDa) and ET(B)-specific bands (49 kDa) were visualized by use of enhanced chemiluminescence Western blotting detection kit (Amersham Biotech).

**Determination of Na+K+-ATPase Activity**

Na+K+-ATPase activity is as described previously.

**Determination of Catecholamines**

Kidneys were homogenized with 0.1 mol/L HClO4 and centrifuged at 6000g for 20 minutes at 4°C. Supernatant, urine, and plasma were flash-frozen and stored at −70°C until assay.

**Determination of Plasma Endothelin-Immunoreactive Levels**

Fifty microliters of plasma was diluted with 1% TCA and centrifuged at 14 000 rpm for 20 minutes at 4°C. Supernatants were loaded into separation columns preequilibrated with 100% acetonitrile and washed with 1% TCA. Peptides were eluted (60% acetonitrile in 1% TCA), lyophilized, and quantified by ELISA (Peninsula).

**Table 1. Characteristics of D2 Mutant Mice**

<table>
<thead>
<tr>
<th>Variable</th>
<th>D2+/+ Mice</th>
<th>D2+/− Mice</th>
<th>D2−/− Mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mo</td>
<td>6−12</td>
<td>6−12</td>
<td>6−12</td>
</tr>
<tr>
<td>Body weight, g</td>
<td>25±1</td>
<td>31±2*</td>
<td>25±1</td>
</tr>
<tr>
<td>Heart weight, % body weight</td>
<td>0.45±0.01</td>
<td>0.42±0.01</td>
<td>0.44±0.02</td>
</tr>
<tr>
<td>Kidney weight, % body weight</td>
<td>1.21±0.08</td>
<td>1.22±0.10</td>
<td>1.20±0.05</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>418±8</td>
<td>439±13</td>
<td>452±8†</td>
</tr>
<tr>
<td>Blood pressure, mm Hg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>104±2†</td>
<td>129±4</td>
<td>128±2</td>
</tr>
<tr>
<td>Diastolic</td>
<td>77±1†</td>
<td>98±3</td>
<td>97±2</td>
</tr>
<tr>
<td>Mean</td>
<td>85±1†</td>
<td>108±3</td>
<td>107±2</td>
</tr>
</tbody>
</table>

*P<0.05 vs D2+/+ or D2−/− mice; †P<0.05 vs D2+/+ mice; ‡P<0.05 vs mutant mice by ANOVA, Newman-Keuls test.

**Results**

**General Characteristics**

D2+/+ mice were heavier than either D2+/+ or D2−/− mice (Table 1). Heart and kidney weights as a percentage of body weight were similar among the groups. Heart rate was significantly elevated in D2−/− mice versus D2+/+ mice. Furthermore, systolic, diastolic, and mean arterial pressures were also higher in mice heterozygous and homozygous for mutated D2 receptor allele compared with wild-type mice. D2 receptors (47 and 98 kDa) were detected in rat striatal tissues (positive control) but not in renal cortical or medullary tissue from rats or from D2−/− or D2+/+ mice (data not shown).

**Effect of Saline Loading**

Basal urine flow rate and sodium excretion were greater in D2−/− mice than in D2+/+ mice (Figure 1). Saline loading increased urine flow and absolute (Figure 1) and fractional sodium (data not shown) excretion in all the mice. However, the increase was greater in D2−/− mice than in D2+/+ mice.
Glomerular filtration rate was similar in D$_2$−/− and D$_2$+/+ mice and was not affected by saline loading. Arterial pressures were not affected by the acute saline load (data not shown).

**Na$^+$.K$^+$.ATPase Activity**

In agreement with reports that D$_2$-like agonists stimulate Na$^+$.K$^+$.ATPase activity in renal tubules, Na$^+$.K$^+$.ATPase activity was lower ($P<0.05$, $t$ test) in both cortical and medullary regions in D$_2$−/− mice (cortex, 22.97±3.26; medulla, 22.09±2.07 nmol of inorganic phosphate per milligram of protein per minute, n=5) than in D$_2$+/+ mice (cortex, 33.45±2.01; medulla, 31.52±2.62 nmol of inorganic phosphate per milligram of protein per minute, n=7).

**Effect of Receptor Ligands on BPs**

**Effects of AT$_1$, and V$_1$ Receptor Antagonists**

AT$_1$ receptor antagonist decreased BP in D$_2$+/+ and D$_2$−/− mice, which indicated that AT$_1$ receptors maintain a tonic control of BP in anesthetized wild-type and mutant mice. In the first 5 minutes after AT$_1$ antagonist administration, however, decrease in BP was greater in D$_2$+/+ than D$_2$−/− mice (Figure 2A). V$_1$ vasopressin antagonist [1-(β-mercaptopropyl-β-cyclopentamethylenepropionic acid)-2-(O-methyl)-tyrosine] arginine vasopressin had minimal effects on BP (Figure 2A).

**Effect of α-Adrenergic Antagonist**

Phentolamine, an α-adrenergic antagonist, markedly decreased BP in D$_2$ mutant and wild-type mice. The magnitude of the decrease in BP was greater in D$_2$−/− than D$_2$+/+ mice (Figure 2B), ultimately resulting in similar BPs at the nadir of the phentolamine effect. Moreover, acute adrenalectomy decreased BP in D$_2$−/− (mean BP in mm Hg before adrenalectomy, 101±5; after adrenalectomy, 52±14; n=3), D$_2$+/+ (mean BP before adrenalectomy, 101±2; after adrenalectomy, 61±4; n=4) and D$_2$+/+ (mean BP before adrenalectomy, 82±2; after adrenalectomy, 47±8; n=2) mice, such that BPs were no longer different among groups.

**Effects of ET(A) and ET(B) Antagonists**

ET(A) antagonist BQ-610 had minimal effects on BP in D$_2$+/+ and D$_2$−/− mice (Figure 2A). In contrast, ET(B1)/ET(B2) antagonist BQ-788 decreased BP in D$_2$−/− but not D$_2$+/+ mice, which indicated that increased activity of ET(B) receptors contributes to elevation of BP in D$_2$ mutant mice (Figure 3A). Because ET(B) receptor subtypes have differential vascular effects (ET(B1) decreases and ET(B2) increases BP), additional studies were performed with ET(B1) antagonist RES-701-1 (Figure 3A). RES-701-1 increased BP to a greater extent in D$_2$−/− than D$_2$+/+ mice.

**Effects of ET-1 and ET(B) Agonist**

Because ET(B1) and ET(B2) effects were increased in D$_2$ mutant mice, we determined the effect of ET-1 on BP. ET-1 0.1 to 1.3 nmol/kg tended to increase BP to a greater extent in D$_2$+/+ than D$_2$−/− mice (maximum increase, 23±5% and 17±5%, respectively; n=3 to 6 per group), but significant differences were not found. ET(B) agonist sarafotoxin S6c also tended to increase BP to a greater extent in D$_2$+/+ than D$_2$−/− mice (maximum increase, 33±10% and 30±4%, respectively) but reached significance only at 0.3 nmol/kg (D$_2$+/+, 21±5% versus D$_2$−/−, 10±1%; $P<0.05$ by $t$ test; n=3 to 6 per group).

**Endothelin Receptor Protein and Endothelin-Like Immunoreactive Levels**

Immunoreactive ET(B) receptors were 3-fold greater in D$_2$−/− than D$_2$+/+ mice (Figure 3B). Plasma immunoreactive endothelin levels were not different between D$_2$+/+ (1.20±0.42 ng/mL) and D$_2$−/− (0.75±0.24 ng/mL) mice, although a trend occurred toward lower values in D$_2$−/− mice. These values are 5 to 100 times greater than that previously reported in mice, because the antibody used cross-reacts with ET-1, ET-2, and big endothelin (Peninsula).

**Catechol Levels**

Renal catechol levels were similar in D$_2$+/+ and D$_2$−/− mice (data not shown). Urinary catechols were also similar except for urinary epinephrine. Epinephrine excretion rates were generally higher before (baseline, urine period 1), during (urine period 2), and after saline loading (urine periods 3 through 5) in D$_2$−/− versus D$_2$+/+ mice (Table 2). Urinary dopamine and norepinephrine tended to increase with saline.
loading in D\textsubscript{2}+/+ mice and reached statistical significance in D\textsubscript{2}−/− mice; the percentage increases in urinary dopamine (85%) and urinary norepinephrine (108%) with saline loading (compared with baseline) were similar in D\textsubscript{2}+/+ and D\textsubscript{2}−/− mice. These changes were associated with increased urine flow but not with glomerular filtration rate (data not shown).

**Discussion**

Our data suggest that disruption of the D\textsubscript{2} dopamine receptor, a member of the family of D\textsubscript{2}-like receptors, increases systolic and diastolic BPs in D\textsubscript{2}+/+ mice and D\textsubscript{2}−/− mice. No gender effect occurred. Presence of hypertension in D\textsubscript{2}+/+ mice may be taken to be an indication that few spare D\textsubscript{2} receptors regulate this phenotype, similar to what has been reported for locomotor and pituitary lactotroph function.\textsuperscript{7,8} The hypertensive phenotype was unlikely to be caused by genetic heterogeneity, because mice have been inbred to the fifth generation.\textsuperscript{7}

Both α\textsubscript{2}-adrenergic and D\textsubscript{2} dopamine receptors are involved in prejunctional inhibition of catecholamine release.\textsuperscript{3,15,16} α\textsubscript{2}-Adrenergic receptor has been shown to inhibit sympathetic outflow, and disruption of this receptor in mice increased BP.\textsuperscript{26} Stimulation of prejunctional D\textsubscript{2}-like receptors also inhibited sympathetic outflow.\textsuperscript{3,15,16} In contrast, stimulation of postsynaptic D\textsubscript{2}-like receptors in the nervous system and arterial vessels increased vascular resistance or BP.\textsuperscript{6,27} The pressor effect of intravenously administered D\textsubscript{2}-like drugs was transient, whereas the peripheral vasodilator effect, presumably caused by actions at prejunctional D\textsubscript{2}-like receptors, was persistent.\textsuperscript{16} The decrease in BP after α-adrenergic blockade in D\textsubscript{2}−/− mice suggests that sympathetic activity may have increased as a result of withdrawal of D\textsubscript{2} receptor actions at prejunctional receptors. Thus, acute adrenalectomy decreased BP such that BPs were no longer different among groups. Moreover, urinary epinephrine levels were elevated in D\textsubscript{2}−/− compared with D\textsubscript{2}+/+ mice; D\textsubscript{2} receptors in the adrenal medulla inhibit epinephrine release.\textsuperscript{27} Similar renal and urinary norepinephrine levels in D\textsubscript{2}+/+ and D\textsubscript{2}−/− mice may be explained by observations of catecholamine metabolism in striatum of D\textsubscript{2}−/− mice. Monoamine levels in striatum were similar in D\textsubscript{2}−/− and D\textsubscript{2}+/+ mice, although dopamine metabolites were increased.\textsuperscript{9,10}

An unexpected finding in these studies was the ability of BQ-788, an ET(B1)/ET(B2) antagonist, to decrease and normalize BP, whereas ET(B1) antagonist RES-701-1 increased BP in D\textsubscript{2}−/− mice without affecting BP in D\textsubscript{2}+/+ mice. ET(A) antagonist BQ-610 had no effect on BP in either D\textsubscript{2}−/− or D\textsubscript{2}+/+ mice. The endothelins (ET-1, ET-2, and ET-3), which are generally vasoconstrictors, exert their actions by means of ET(A) and ET(B) receptors.\textsuperscript{18−20,25,28} However, endothelin can also mediate vasodilation.\textsuperscript{19,20,25,28} On the basis of pharmacological evidence, 2 types of ET(B) receptors have been postulated: ET(B1), which is a relaxant,
and ET(B2) which is a constrictor. In ET(B) knock-out mice, both vasodilatory and vasoconstrictor effects of ET(B) receptors were eliminated, which suggests that ET(B1) and ET(B2) receptors are the same receptor. The difference in their actions may be related to the sites at which these receptors are expressed. For example, ET(B1) (ET[B1]) receptors expressed in endothelial cells are vasodilatory because of their linkage to nitric oxide and prostaglandins; the ability of prejunctional ET(B) (ET[B1]) receptors to inhibit catecholamine release may also contribute to decreasing vascular resistance. Elimination of the ET(B1)-mediated stimulation of endothelial prostacyclin production has been suggested to be the cause of hypertension in ET(B)-deficient mice. If an ET(B1)-mediated increase in endothelial or prostacyclin production does not occur, however, then the vasoconstrictor effect of ET(B2) would become unopposed, which would result in hypertension. The anticipated inhibitory effect of ET(B1) on catecholamine release would partially offset the absence of the usual inhibitory effect of D2 receptors on catecholamine release in this model. This occurrence may explain the modest changes in urinary catechol in D2−/− mice.

Interestingly, ET(B) expression was 5 times greater in D2−/− than D2+/+ mice. Absence of D2 receptors conceivably could have led to increased vasodilatory ET(B1) receptors and vasoconstrictor ET(B2) receptors. Because D2 receptors are expressed at the junction of adventitia and tunica media, disruption of D2 receptors should affect expression of ET(B1) and ET(B2) receptors in the tunica media–adventitia but not ET(B1) in the tunica intima because no dopamine receptors are expressed in this blood vessel layer. Minimal differential effect of ET-1 and the ET(B1) agonist sarafotoxin S6c occurred on BP in D2+/+ versus D2−/− mice, presumably because ET(B1) expression in tunica media was not altered in D2−/− mice. The predominant effect in D2 mutant mice was an increase in ET(B2) action, however, because the D2 mutant mice were hypertensive. Hence, the BP-lowering effect of ET(B1)/ET(B2) antagonist BQ-788 in D2 mutant mice and the greater increase in BP in D2 mutant versus D2+/+ mice after the ET(B1) antagonist RES-101–1. Although renin levels were not measured in these studies, the greater hypertensive response to AT1 blockade in D2 wild-type versus D2−/− mice is suggestive of decreased activity of the renin-angiotensin system in D2−/− mice. ET(B) receptors have been reported to inhibit renin gene expression in mouse juxtaglomerular cells.

The site of interaction between D2 dopamine receptors and ET(B) receptors was not determined in the present studies. Dopamine, dopamine receptors, endothelin, and ET(B) receptors have been found in brain and spinal regions known to control cardiovascular function. Depletion of dopamine production in the striatum has been reported to decrease ET receptors. Decreased clearance of dopamine in D2−/− mice may have led to upregulation of vasoconstricting ET(B2) receptors in the tunica media of resistance vessels. Another explanation may be that the absence of inhibitory effect of D2 receptors on ET(B1) receptors in adrenal medulla of D2−/− mice could have led to the increase in circulating epinephrine.

We have reported that disruption of the D2 receptor in mice leads to development of renin-dependent hypertension and decreased ability to excrete sodium load. In the present studies, D2−/− mice not only had a greater basal urine flow rate and sodium excretion than D2+/+ mice but also responded to saline loading with greater natriuresis and diuresis than the D2+/+ mice. Increased sodium excretion in the D2−/− mice was associated with lower Na+,K+-ATPase activity, the cause of which remains to be determined. However, ET(B) receptors have been reported to decrease chloride transport at the thick ascending limb of Henle. Pressure natriuresis also may have contributed to increased sodium excretion in the D2−/− mice.

In summary, on the basis of our examination of D2 receptor–deficient mice, we conclude that D2 dopamine receptors expressed on sympathetic neurons normally act to inhibit sympathetic outflow from the nervous system. When 50% of the D2 receptor population is depleted, concomitant increases occur in sympathetic outflow and expression of ET(B) receptors in several tissues, including liver and, presumably, vascular smooth muscle cells as well. The absence of inhibitory tone on sympathetic outflow mediated by the D2 dopamine receptor coupled with increased ET(B) activity may predispose the animal to hypertension.

Acknowledgments

The present work was supported in part by grants from the National Institutes of Health HL-58536, HL-23081, DK-39308, and DK-52612. We also thank Courtney Holmes for performing the catechol assays.

References

mutant motor phenotype in mice lacking dopamine D2 and D3 receptors. 


11. L’hirondel M, Cheramy A, Godeheu G, Artaud F, Saiardi A, Borrelli E, 
Glowninski J. Lack of autoreceptor-mediated inhibitory control of 
dopamine release in striatal synaptosomes of D2 receptor-deficient mice. 
Brain Res. 1998;792:253–262.

T, Wong A, St Lezin E, Lau D, Szpirer C, Szpirer J, Kurtz TW. Genetic 
isoilation of a region of chromosome 8 that exerts major effects on blood 
pressure and cardiac mass in the spontaneously hypertensive rat. J Clin 

13. Cravchik A, Sibley DR, Gejman PV. Functional analysis of the human D2 
dopamine receptor missense variants. J Biol Chem. 1996;271: 
26013–26017.

14. Thomas GN, Tomlinson B, Critchley JA. Modulation of blood pressure 
and obesity with the dopamine D2 receptor gene Taq1 polymorphism. 

15. Touda K, Touda S, Masuyama Y, Goldstein M. Alterations in catechol-
amine release in the central nervous system of spontaneously hyper-

16. Nagahama S, Chen YF, Lindheimer MD, Oparil S. Mechanism of the 
depressor action of LY171555, a selective dopamine D2 receptor agonist, 

17. Bealer SL, Abell SO. Paraventricular nucleus histamine increases blood 

Inotropic effects of endothelin-1: interaction with molsidomine and with 

19. Allcock GH, Warner TD, Vane JR. Roles of endothelin receptors in the 
regional and systemic vascular responses to ET-1 in the anesthetized 

20. Gellai M, Fletcher T, Pullen M, Nambi P. Evidence for the existence of 
endothelin-B receptor subtypes and their physiological roles in the rat. 

21. Fildes RD, Eisner GM, Calcagno PL., Jose PA. Renal α-adrenoceptors 

Endothelin-1 induces liver vasoconstriction through both ETA and ETB 

23. Swann AC. (Na⁺,K⁺)-adenosine triphosphatase regulation by the sympa-
thetic nervous system: effects of noradrenergic stimulation and lesions in 

Simultaneous measurement of plasma and brain extracellular fluid concen-
trations of catechols after yohimbine administration in rats. Brain Res. 

25. Ohuchi T, Kuwaki T, Ling GY, Dewit D, Ju KH, Ondera M, Cao MH, 
Yanagisawa M, Kumada M. Elevation of blood pressure by genetic and 
pharmacologically disrupted of the ETβ receptor in mice. Am J Physiol. 

26. Makaritsis KP, Johns C, Gavras I, Altman JD, Handy DE, Bresnahan MR, 
Gavras H. Sympathoinhibitory function of the α2c-adrenergic receptor 

27. Mannelli M, Ianni L, Lazzeri C, Castellani W, Pupilli C, La Villa G, 
Barletta G, Serio M, Franchi F. In vivo evidence that endogenous 
34:398–402.


29. Mizuguchi T, Nishiyama M, Moroi K, Tanaka H, Saito T, Masuda Y, 
Masaki T, de Wit D, Yanagisawa M, Kimura S. Analysis of two phar-
macologically predicted endothelin B receptor subtypes by using the 
endothelin B receptor gene knockout mouse. Br J Pharmacol, 1997;120: 
1427–1430.

Kimura T, Sato S. Facilitation and inhibition by endothelin-1 of adrenal 
397:55–61.

31. Amenta F, Barili P, Bronzetti E, Felici L, Mignani F, Ricci A. Local-
ization of dopamine receptor subtypes in systemic arteries. Clin Exp 

32. Rithhaler T, Delta Bruuna R, Kramer BK, Kurtz A. Endothelins inhibit 
cyclic-AMP induced renin gene expression in cultured mouse juxtaglo-

33. van den Buse M, Webber KM. Endothelin and dopamine release. Prog 

34. Belloni AS, Pacheco YG, Markowska A, Andreis PG, Meneghelli V, 
Malendowicz LK, Musso K, Wiesendanger MG. Distribution and functional signif-
icance of the endothelin receptor subtypes in the rat adrenal gland. Cell 

35. Plato CF, Pollock DM, Garvin JL. Endothelin inhibits thick ascending 
limb chloride flux via ET(B) receptor-mediated NO release. Am J Physiol 
Adrenergic and Endothelin B Receptor-Dependent Hypertension in Dopamine Receptor Type-2 Knockout Mice

Xiao Xi Li, Martin Bek, Laureano D. Asico, Zhiwei Yang, David K. Grandy, David S. Goldstein, Marcelo Rubinstein, Gilbert M. Eisner and Pedro A. Jose

Hypertension. 2001;38:303-308
doi: 10.1161/01.HYP.38.3.303

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2001 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/38/3/303

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/